265 related articles for article (PubMed ID: 19169683)
1. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.
Ramanathan RK; Belani CP; Singh DA; Tanaka M; Lenz HJ; Yen Y; Kindler HL; Iqbal S; Longmate J; Mack PC; Lurje G; Gandour-Edwards R; Dancey J; Gandara DR
Cancer Chemother Pharmacol; 2009 Sep; 64(4):777-83. PubMed ID: 19169683
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
3. Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial.
Ravaud A; Hawkins R; Gardner JP; von der Maase H; Zantl N; Harper P; Rolland F; Audhuy B; Machiels JP; Pétavy F; Gore M; Schöffski P; El-Hariry I
J Clin Oncol; 2008 May; 26(14):2285-91. PubMed ID: 18467719
[TBL] [Abstract][Full Text] [Related]
4. HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib.
Peck J; Wei L; Zalupski M; O'Neil B; Villalona Calero M; Bekaii-Saab T
Oncology; 2012; 82(3):175-9. PubMed ID: 22433475
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.
Philip PA; Mahoney MR; Allmer C; Thomas J; Pitot HC; Kim G; Donehower RC; Fitch T; Picus J; Erlichman C
J Clin Oncol; 2005 Sep; 23(27):6657-63. PubMed ID: 16170173
[TBL] [Abstract][Full Text] [Related]
6. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma.
Wülfing C; Machiels JP; Richel DJ; Grimm MO; Treiber U; De Groot MR; Beuzeboc P; Parikh R; Pétavy F; El-Hariry IA
Cancer; 2009 Jul; 115(13):2881-90. PubMed ID: 19399906
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.
Thomas MB; Chadha R; Glover K; Wang X; Morris J; Brown T; Rashid A; Dancey J; Abbruzzese JL
Cancer; 2007 Sep; 110(5):1059-67. PubMed ID: 17623837
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial.
Yen Y; Lim DW; Chung V; Morgan RJ; Leong LA; Shibata SI; Wagman LD; Marx H; Chu PG; Longmate JA; Lenz HJ; Ramanathan RK; Belani CP; Gandara DR
Am J Clin Oncol; 2008 Aug; 31(4):317-22. PubMed ID: 18845988
[TBL] [Abstract][Full Text] [Related]
9. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin.
Gish RG; Porta C; Lazar L; Ruff P; Feld R; Croitoru A; Feun L; Jeziorski K; Leighton J; Gallo J; Kennealey GT
J Clin Oncol; 2007 Jul; 25(21):3069-75. PubMed ID: 17634485
[TBL] [Abstract][Full Text] [Related]
10. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma.
Park JW; Finn RS; Kim JS; Karwal M; Li RK; Ismail F; Thomas M; Harris R; Baudelet C; Walters I; Raoul JL
Clin Cancer Res; 2011 Apr; 17(7):1973-83. PubMed ID: 21349999
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.
Rimassa L; Santoro A
Expert Rev Anticancer Ther; 2009 Jun; 9(6):739-45. PubMed ID: 19496710
[TBL] [Abstract][Full Text] [Related]
14. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas.
Bekaii-Saab T; Markowitz J; Prescott N; Sadee W; Heerema N; Wei L; Dai Z; Papp A; Campbell A; Culler K; Balint C; O'Neil B; Lee RM; Zalupski M; Dancey J; Chen H; Grever M; Eng C; Villalona-Calero M
Clin Cancer Res; 2009 Sep; 15(18):5895-901. PubMed ID: 19737952
[TBL] [Abstract][Full Text] [Related]
15. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma.
Vora SR; Zheng H; Stadler ZK; Fuchs CS; Zhu AX
Oncologist; 2009 Jul; 14(7):717-25. PubMed ID: 19581525
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathogenesis and targeted therapy of hepatocellular carcinoma.
Zender L; Kubicka S
Onkologie; 2008 Oct; 31(10):550-5. PubMed ID: 18854656
[TBL] [Abstract][Full Text] [Related]
17. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study.
Barbare JC; Bouché O; Bonnetain F; Dahan L; Lombard-Bohas C; Faroux R; Raoul JL; Cattan S; Lemoine A; Blanc JF; Bronowicki JP; Zarski JP; Cazorla S; Gargot D; Thevenot T; Diaz E; Bastie A; Aparicio T; Bedenne L
Eur J Cancer; 2009 Jul; 45(10):1788-97. PubMed ID: 19303768
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck.
Harrington KJ; El-Hariry IA; Holford CS; Lusinchi A; Nutting CM; Rosine D; Tanay M; Deutsch E; Matthews J; D'Ambrosio C; Turner SJ; Pandeshwara JS; Bourhis J
J Clin Oncol; 2009 Mar; 27(7):1100-7. PubMed ID: 19171712
[TBL] [Abstract][Full Text] [Related]
20. Growth factors as therapeutic targets in HCC.
Furuse J
Crit Rev Oncol Hematol; 2008 Jul; 67(1):8-15. PubMed ID: 18434184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
